GE HealthCare has launched the Invenia Automated Breast Ultrasound (ABUS) Premium, an artificial intelligence (AI)-driven 3D ultrasound system.
The new system is designed to enhance breast cancer screening, particularly for patients with dense breast tissue. It aims to optimise scanning efficiency and support early detection efforts by streamlining imaging procedures and accelerating clinical workflows.
The ABUS Premium integrates AI-powered Verisound tools, including Scan Quality Assessment, which enables immediate evaluation of breast coverage and positioning during the exam. It also features Auto Nipple Detection, ensuring consistency in nipple marker placement.
A Fast Scan function increases scanning speed by up to 40% compared to its predecessor, Invenia ABUS 2.0, while the cSound Imageformer technology enhances image clarity by automatically adjusting focus at every pixel.
According to GE HealthCare, clinicians can review and interpret 3D ultrasound datasets remotely or in practice settings using the Invenia ABUS Viewer, which incorporates AI-driven tools to aid in the detection and classification of breast lesions. These capabilities support workflow efficiency and may help address workforce shortages in radiology.
The ABUS Premium system is designed as a non-invasive alternative to traditional screening methods, eliminating the need for ionising radiation or contrast agents.
Its imaging technology may assist in reducing unnecessary biopsies by providing clearer differentiation between benign and malignant tumours, potentially enabling earlier intervention, said GE HealthCare.
Equipped with a Reverse Curve transducer, the system conforms to breast anatomy while offering adjustable compression levels for a more tailored patient experience.
GE HealthCare comprehensive care ultrasound CEO Karley Yoder said: “Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages.
“Invenia ABUS Premium equipped with AI has the potential to optimise clinicians’ screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts.
“Invenia ABUS Premium is designed to help deliver the best possible outcomes for patients while also prioritising the patient experience with features to improve scan speed and enhance comfort during an exam.”
GE HealthCare plans to introduce the ABUS Premium in key markets throughout 2025, following its premarket approval (PMA) from the US Food and Drug Administration (FDA).
